scm logo

SCM Lifescience, Inc. held its first Non-Deal Road Show (NDR) on June 7-8 to explain the essential value of the company to domestic institutional investors in terms of research, clinical, and business feasibility.

Bio-only researchers and fund managers from a total of seven institutional investors with operating assets ranging from at least 593.7 billion won to up to 3939 billion won participated.

This corporate briefing session was not the previous CEO-centered event-oriented IR but was attended by Hyung-Nam Oh, Executive Vice President of IR/PR, and three headquarters managers. 

At the briefing session, we explained that there are only two source technologies for stem cell isolation and culture in the world. and we emphasized the importance and superiority of the Subfractionation Culturing Method of SCM Lifesciences Inc. compared to the Density-Gradient Centrifugation Method of Osiris, which is mainly used for the separation and culture of existing stem cells.

Osiris, a bio company based on stem cell technology established in 1992, was active in 2008 by signing a strategic partnership with the bio company Genzyme for the development and commercialization of stem cell therapeutics. However, the Chronic Graft-versus-Host Disease(GvHD) treatment eventually failed the FDA's phase 3 clinical trial approval, and the partnership ended when Sanofi acquired Genzyme in 2011.

Since then, Osiris has sold The culture-expanded mesenchymal cell business to Mesoblast for $100M and was completely acquired and merged with Smith+Nephew for $660M in 2019.

Mesoblast(NASDAQ market cap of 400M $), which acquired the mesenchymal stem cell business, also disclosed as an analysis content that the FDA approval of Remestem Cell-L (steroid-refractory pediatric acute Graft-versus-Host Disease) was rejected in 2020.

It was found that this situation did not meet the expectations of the stem cell business using the Density-Gradient Centrifugation Method of Osiris, which secured a technological edge in the early adult stem cell therapy market.

Accordingly, it was a decisive opportunity for the world's leading pharmaceutical and bio companies, which paid a lot of attention to developing stem cell treatments in the early 2010s, to turn their attention to immunotherapy.

However, SCM Lifescience, as the last player in stem cell isolation and culture source technology, was confident that it could explain a clear mechanism for stem cell treatment. And we emphasized the need for the emergence of stem cell therapeutics that offer fundamental treatment rather than simple symptom relief in the market. To this end, we emphasized that from the early stage of clinical development, we have faithfully proceeded with the process of proving the difference from the original stem cell isolation and culturing technology and making a thesis.

In addition, we explained that all global patent rights for the Subfractionation Culturing Method of SCM Lifescience, Inc. were secured, and the strategic advantage of this patent portfolio is equivalent to the material patent rights of chemical therapeutics.

As a result of checking the feedback of bio researchers and fund managers of the participating institutional investors, as information on CoImmune was repeatedly announced in 2020, the company's main pipeline was shown as CoImmune's immune cell therapy.

However, they said it was refreshing to learn in detail that SCM Lifescience is actively conducting research and clinical trials on its core pipeline through this company briefing session.

In addition, they added that he felt the sincerity of the company doing its best in anticipation of the results of the Phase 1/2a clinical trial for severe acute pancreatitis in August.

In the future, SCM Lifescience, Inc. will update specific marketability and business feasibility information on clinical pipelines.

Also, we will continue the company briefing session with the results of Severe acute pancreatitis in August.